China (Mainland)
Fevipiprant 872365-14-5 Anti-hair loss powders CAS NO.872365-14-5
- FOB Price: USD: 1,000.00-1,000.00 /Metric Ton Get Latest Price
- Min.Order: 1 Gram
- Payment Terms: L/C,D/A,D/P,T/T,Other
- Available Specifications:
99% purity(1-10)Metric Ton
- Product Details
Keywords
- Fevipiprant
- Fevipiprant powder
- anti hair loss
Quick Details
- ProName: Fevipiprant 872365-14-5 Anti-hair loss...
- CasNo: 872365-14-5
- Molecular Formula: C19H20N2O2
- Appearance: powder
- Application: anti hair loss
- DeliveryTime: 12-15 days
- PackAge: Foil Bag, According to Client's Requir...
- Port: SHANGHAI
- ProductionCapacity: 10000 Kilogram/Week
- Purity: 99%
- Storage: store in cool and dry place
- Transportation: FedEx DHL EMS or by Sea
- LimitNum: 1 Gram
Superiority
1, High quality with competitive price:
1) Standard:BP/USP/EP/Enterprise standard
2) All Purity≥99%
3) We are manufacturer and can provide high quality products with factory price.
2, Fast and safe delivery
1) Parcel can be sent out in 24 hours after payment.Tracking number available
2) Secure and discreet shipment.Various transportation methods for your choice.
3) Customs pass rate ≥99%
4) We have our own agent/remailer/distributor who can help us ship our products very fast and safe,
and we have stock in there for transferring.
3,We have clients throughout the world.
1) Professional service and rich experience make customers feel at ease, adequate stock and fast delivery meet their desire.
2) Market feedback and goods feedback will be appreciated, meeting customers's requirement is our responsibility.
14) High quality,competitive price,fast delivery ,first-class service gain the trust and praise from the customers.
Details
Fevipiprant
Fevipiprant, also known as NVP-QAW039 or QAW039, is an oral active and potent CRTh2 receptor antagonist and potentially useful for asthma treatment. [(3)H]-QAW039 displayed high affinity for the human CRTh2 receptor (1.14 ± 0.44 nM) expressed in Chinese hamster ovary cells, the binding being reversible and competitive with the native agonist prostaglandin D2(PGD2). QAW039 was also a potent inhibitor of PGD2-induced cytokine release in human Th2 cells. Fevipiprant reduces eosinophilic airway inflammation and is well tolerated in patients with persistent moderate-to-severe asthma and raised sputum eosinophil counts despite inhaled corticosteroid treatment. Fevipiprant demonstrates a favorable safety profile.
